Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

Pharmacopsychiatry

Volumn 34, Issue 6, 2001, Pages 238-241

  Lam, L C W ^a   Chiu, H F K ^a   Garcia Barcelo, M M ^a   Ungvari, G S ^a   Tang, W K ^a   Lam, V K L ^a   Kwong, S L ^a   Lau, B S T ^a   Kwong, P P K ^a   Waye, M M Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CYP 2D6 genotyping; Schizophrenia; Tardive dyskinesia

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE PREDISPOSITION; ENZYME ANALYSIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA;

EID: 0035189653     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18035     Document Type: Article

References (32)

1. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
2. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
3. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
4. A rating scale for drug-induced akathisia
5. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
6. Geographical/Interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
7. Prevalence of tardive dyskinesia, tardive dystonia and respiratory dyskinesia in Chinese psychiatric patients in Hong Kong
8. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population
9. Identification of the primary gene defect at cytochrome P450 CYP2D locus
10. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
11. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
12. Genetic polymorphismus for drug metabolism (CYP 2D6) and tardive dyskinesia in schizophrenia
13. The evolving science of pharmacogenetics: Clinical and ethnic perspectives
14. Effects of the CYP2D6 10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
15. How to examine patients using the Abnormal Involuntary Movement Scale
16. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia
17. Tardive dyskinesia and debrisoquine-4-hydroxylase (CYP 2D6) genotype in Japanese schizophrenics
18. The Brief psychiatric rating scale
19. Research diagnoses for tardive dyskinesia
20. A rating sclae for extrapyramidal side effects
21. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population
22. Effects of the CYP 2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
23. Tardive dyskinesia: Who is at risk?
24. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6
25. R296C and other CY2D6 mutations in Chinese
26. G169R mutation diminishes the metabolic activity of Cyp 2D6 in Chinese
27. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
28. Anchoring the BPRS: An aid to improve reliability
29. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: A meta-analysis